Conference on retroviruses and opportunistic infections (CROI) held on March 8-11, 2020 at Boston, MA, USA

  1. Hoy J, Kerr SJ, Hans D, Pocock N, Carr A for the ZeST Study Group. Change in Trabecular Bone Score (TBS) after zoledronic infusion or TDF switch.
  2. Han WM, Colby DJ, Khlaiphuengsin A, Apornpong T, Kerr SJ, Ubolyam S, Kroon E, Phanuphak N, Avihingsanon A, Ruxrungtham K, Phanuphak P, Avihingsanon A, Luscombe CA, Ewart GD, Thomson AS, Supparatpinyo K, Gatechompol S, Miller M, Murphy R. Phase II trial of VPU inhibitor BIT 225 in combination with antiretroviral therapy.
  3. Kim JH, Jiamsakul A, Kiertiburanakul S, Huy BV, Khusuwan S, Kumarasamy N, Ng OT, Ly PS, Lee M, Chan Y, Gani YM, Azwa I, Avihingsanon A, Merati TP, Pujari S, Chaiwarith R, Zhang F, Tanuma J, Do CD, Ditangco R, Yunihastuti E, Ross J and Choi JY on behalf of IeDEA Asia-Pacific. Patterns and prognosis of holding regimens for patients with HIV in Asian countries.
  4. Singh KP, Zerbato JM, Zhao W, Braat S, Tennakoon S, Solomon A, Matthews G, Fairley CK, Sasadeusz J, Crane M, Avihingsanon A, Audsley J, Lewin SR. Liver disease progression in HIV-HBV coinfection on ART is associated with high HMGB1.
  5. Wang XQ, Zerbato JM, Avihingsanon A, Fisher K, Horsburgh BA, Solomon A, Audsley J, Singh KP, Zhao W, Crane M, Lewin SR. HBV-related inflammation is linked to the level of genetically intact HIV proviruses.
  6. Han WM, Colby D, Khlaiphuengsin A, Apornpong T, Kerr S, Ubolyam S, Kroon E, Phanuphak N, Avihingsanon A, Ruxrungtham K, Phanuphak P, Tangkijvanich P. Large hepatitis C transmission cluster identified among HIV-positive MSM in Bangkok.
  7. Gatechompol S, Avihingsanon A, Zheng L, Bao Y, Kerr SJ, Kumarasamy N, Hakim JG, Malderelli F, Gorelick R, Welker JL, Lifson JD, Hosseinipour MC, Eron JJ, Ruxrungtham K, for the ACTG NWCS 425 team. Risk and prevalence of residual viremia after ART in resource-limited countries.